In May 2016, the company announced it would acquire Anacor Pharmaceuticals for $5. 2 billion, expanding the companies portfolio in both inflammation and immunology drugs areas. On their final trading day, Anacor shares traded for $99. 20 each, giving Anacor a market capitalisation of $4. 5 billion. In August, the company made a $40 million bid for the assets of the now bankrupt BIND Therapeutics through the U. S. Bankruptcy Court. The same month, the company announced it would acquire Bamboo Therapeutics for $645 million, expanding the company's gene therapy offerings. Later, in August, the company announced the acquisition of cancer drug-maker - Medivation - for $14 billion. On Medivation's final day of trading, its shares were valued at $81. 44 each, giving an effective market capitalisation of $13. 52 billion. Two days later, Pfizer announced it would acquire AstraZenecas small-molecule antibiotics business for $1. 575 billion merging it into its Essential Medicines business In the same month the company licensed the anti-CTLA4 monoclonal antibody, ONC-392, from OncoImmune.